PEDRO ENRIQUE DORLHIAC LLACER

(Fonte: Lattes)
Índice h a partir de 2011
7
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico

Filtros

Limpar filtros

Configurações

Autor e Coautores FMUSP-HC Normalizados: MARIANA GOMES SERPA ×

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • article 7 Citação(ões) na Scopus
    Evaluation of Long-Term Outcomes, Cytogenetic and Molecular Responses with Imatinib Mesylate in Early and Late Chronic-Phase Chronic Myeloid Leukemia: A Report from a Single Institute
    (2012) BENDIT, Israel; SANABANI, Sabri Saeed; CONCHON, Monika; SERPA, Mariana; NOVAES, Mafalda Megumi Yoshinaga; NARDINELLI, Luciana; PEREIRA, Thales Dalessandro Meneguin; TUCUNDUVA, Luciana; FERREIRA, Patricia de Barros; DORLHIAC-LLACER, Pedro Enrique; CHAMONE, Dalton de Alencar Fischer
    Here we compare the management and survival outcomes of chronic myeloid leukemia (CML) patients who had early or late imatinib mesylate (IM) therapy. The cytogenetic and molecular responses of 189 CML patients were analyzed. Of this group, 121 patients were classified as the early chronic phase (ECP) group and started IM within 12 months of diagnosis. The other 68 patients were classified as the late chronic phase (LCP) group who had been treated with interferon (IFN)-alpha-2 and crossed over to IM more than 12 months after diagnosis. The overall rates of complete cytogenetic response (CCyR) and major molecular response (MMR) at last follow-up were 83.6 and 78.1% in the ECP and LCP groups, respectively. The CCyR rates were 89.3 (for ECP patients) versus 73.5% (for LCP patients; p < 0.0001). At last follow-up, 82.4% ECP and 64.2% LCP patients had achieved an MMR (p < 0.0001). No significant differences were noted between the two groups with regard to survival outcomes. Our experience reveals that IM is an effective rescue therapy in most CML LCP patients who are intolerant or in whom IFN-alpha therapy fails. Such therapeutic options should be considered in LCP patients, particularly in countries where IM may not be available.
  • article 1 Citação(ões) na Scopus
    Dasatinib Overrides Imatinib Resistance Mediated by the F359I Residue Mutation in Two Patients with Chronic Myeloid Leukemia
    (2012) SERPA, Mariana; SANABANI, Sabri S.; DORLHIAC-LLACER, Pedro Enrique; NARDINELLI, Luciana; FERREIRA, Patricia de Barros; MARTINS, Thays Fernanda Borges; SEGURO, Fernanda; BENDIT, Israel
    Despite the beneficial effects of imatinib mesylate, some patients may either not respond or respond suboptimally. Here, we report two chronic myelogenous leukemia patients; one had a suboptimal response according to European LeukemiaNet criteria (a major molecular response was not achieved after 18 months of standard-dose imatinib therapy) and the other had failure with a standard dose of imatinib. At the time of the suboptimal response in patient 1 and the failure in patient 2, we were able to detect the F359I mutation in the BCR-ABL tyrosine kinase domain using DNA sequencing in both patients. Therefore, it was decided to change the therapeutic regimen to dasatinib at a dose of 100 mg once daily in both patients. This change resulted in the achievement of complete cytogenetic remission in patient 1 after 4 months and a major molecular response within 2 and 3 months in both patients. Detection of the F359I mutation in our two cases likely explains the suboptimal response to imatinib in case 1 and the failure in case 2. This implies that in such cases dasatinib should be considered to effectively suppress the mutated clones.